Exabis Library
Welcome to the e-CCO Library!
OP20 The gut microbiota during biological therapy for inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP20: Perianal fistulas are characterised by expansion of interleukin-22 producing invariant natural killer T-cells and CD4+ T-cells which drive dysregulation of the extracellular matrix
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP20: Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP20: The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP21: ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP21: COVID-19 morbidity/mortality and vaccination against SARS-CoV-2 in patients with Inflammatory Bowel Disease in Poland: Nationwide Data
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP21: COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP21: Predictive value of Milan Ultrasound Criteria in Ulcerative Colitis: A prospective observational cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP22 Crohn’s disease exclusion diet reduces bacterial dysbiosis towards healthy controls in paediatric Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP22: Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP22: Factors independently associated with fatigue in IBD: Results from the baseline dataset of the PREdiCCt study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP22: The risk of cancer in pediatric-onset immune-mediated inflammatory diseases – a nationwide Danish study from 1980-2018.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP23: Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in Catalonia
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal models
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP23: Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP23: The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM